Theodoros P. Vassilakopoulos

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2017 · 985 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo et al. · The Lancet Haematology · 2020 · 337 citations · Full text

Medicine, Hematology, Oncology +11

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee et al. · Blood · 2019 · 329 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

Marie‐Christine Kyrtsonis, Theodoros P. Vassilakopoulos, Sotirios Sachanas et al. · British Journal of Haematology · 2007 · 129 citations

Medicine, Hematology, Oncology +13

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care

Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Andreas Katsigiannis et al. · The Oncologist · 2012 · 124 citations · Full text

Medicine, Oncology, Pharmacotherapy +15